• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    vTv Therapeutics Announces Presentations on its Diabetes Product Candidates TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity

    Investing News Network
    Apr. 12, 2016 08:43AM PST
    Biotech Investing

    HIGH POINT, N.C.–(BUSINESS WIRE)–vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected for oral and poster presentations on its diabetes product candidates, TTP273 and TTP399 at the Keystone Symposia on New Therapeutics …

    HIGH POINT, N.C.–(BUSINESS WIRE)–vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected for oral and poster presentations on its diabetes product candidates, TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity. The symposia will take place from April 17 – 20, 2016 in La Jolla, CA.
    TTP273
    Oral Presentation Details:

    • Presentation Title: Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting
    • Session Date: Wednesday, April 20, 2016
    • Session Time: 8:30 a.m. – 11:30 a.m. PDT

    Poster Details:

    • Poster Title: Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting
    • Poster Number: 1025
    • Poster Session: 1
    • Session Date: Monday, April 18, 2016
    • Session Time: 11:45 a.m. – 10:00 p.m. PDT

    TTP399
    Poster Details:

    • Poster Title: The Importance of Tissue Selectivity and Preservation of the Physiological Regulation when Targeting Key Metabolic Regulators as Glucokinase
    • Poster Number: 2040
    • Poster Session: 2
    • Session Date: Tuesday, April 19, 2016
    • Session Time: 11:30 a.m. – 10:00 p.m. PDT

    A copy of the posters will be made available in the News & Events section of the Company’s website following the presentations.
    About Type 2 Diabetes
    Type 2 diabetes is the body’s inability to properly use insulin to control sugar in the bloodstream. It is the most common type of diabetes (representing 90 to 95% of diabetes patients), imposing a growing burden on healthcare systems globally. The goal of maintaining A1c levels below 7.0% is elusive for patients with this life-long disease. In addition to unregulated glucose, diabetics commonly have a variety of co-morbidities, including heart disease, stroke, high blood pressure, blindness, kidney disease, amputations, dental disease, and central and peripheral nervous system impairment.
    About vTv Therapeutics Inc.
    vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

    product candidatesposter presentationsdrug candidatesla jolla
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×